ADDEX THERAPEUTICS LIMITED

ISIN: CH0029850754 WKN: 2985075 Asset Class: Stock

Company

addex

2024/08/16 17:31:02

Price **0.05**

CHF

Difference -10.34%(-0.01)



Contact Details

ADDEX THERAPEUTICS

LTD.

Tel: +41-22-884-15-55 Fax: +41-22-884-15-56

9, Chemin des Mines,

1202 Genf

Web:

Plan-les-Ouates

http://www.addextherapeutics.com

<u>E-mail:</u>

info@addextherapeutics.com

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	23	20	22	20:	21
Financial figures	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	4,233,000		7,825,000		21,924,000	
Common stock capital		1,843,000		1,153,000		49,272,000
Fixed assets	407,000		453,000		600,000	
Equity capital of a company		1,144,000		4,909,000		16,913,000
Cash and cash equivalents	3,865,000		6,957,000		20,484,000	
Accrued liabilities		443,000		0		1,281,000
Other assets	-		-		-	
Current liabilities		2,893,000		3,282,000		4,134,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		603,000		87,000		1,475,000
Different income		-		-		-
Other liabilities		89,000		0		0
Total assets	4,641,000	4,641,000	8,278,000	8,278,000	22,524,000	22,524,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	23	24	28
Equity ratio	24.66%	59.30%	75.09%
Debt-equity ratio	305.47%	68.62%	33.17%

Others

	2023	2022	2021
Tax Expense Rate	0.00%	0.00%	0.00%

ADDEX THERAPEUTICS LIMITED

ISIN: CH0029850754 WKN: 2985075 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	1,617,000	1,444,000	2,934,000
Net income	-10,556,000	-20,804,000	-15,351,000
EBIT	-11,206,943	-21,977,601	-16,172,113
Operating income before taxes	-10,556,000	-20,804,000	-15,351,000
Cash Flow	-7,950,000	-16,456,000	-14,762,000
Net interest income	42,000	-19,000	-57,000
Research and development expenses	6,759,000	14,447,000	12,567,000
Income taxes	0	0	0
Result from investments in subsidaries, associates and other	0	0	0
Revenues per employee	74,348	63,662	110,837

Board of Direct	tors	
Isaac Manke	Member of the administrative board	
Raymond Hill	Member of the administrative board	
Roger Mills	Member of the administrative board	
Jake Nunn	Member of the administrative board	
Vincent Lawton	Chairman of the administrative boar	

Members of Management Board		
Timothy Dyer	Chairman of Managing Board	
Lénaic Teyssédou	Member of Executive Committee	
Mikhail Kalinichev	Member of Executive Committee	
Roger Mills	Member of Executive Committee	